Health‐related quality of life Dementia‐specific quality of life measure (QUALIDEM) (higher scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
no estimate extracted
33 participants
Very low
Activities of daily living · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
no estimate extracted
499 participants
Very low
Asthma control · people with asthma
1 finding from 1 review
QoL · people with asthma
1 finding from 1 review
Venous diameter (high volume versus low volume isotonic exercise training) · CKD patients who underwent AVF creation
1 finding from 1 review
Blood flow in the inflow artery (high volume versus low volume isotonic exercise training) · CKD patients who underwent AVF creation
1 finding from 1 review
HRQoL: using EQ‐5D (range from 0 to 1; higher values indicate better quality of life · adults with displaced and undisplaced hip fractures
1 finding from 1 review
Functional status, early (within 4 months): using HHS (range from 0 to 100) and Johansen hip score (range from 0 to 100); higher scores indicate better function · adults with displaced and undisplaced hip fractures
1 finding from 1 review
HRQoL: using EQ‐5D (range from 0 to 1; higher values indicate better quality of life · adults with displaced and undisplaced hip fractures
1 finding from 1 review
Functional status, early (within 4 months): using HHS (range from 0 to 100) and Johansen hip score (range from 0 to 100); higher scores indicate better function · adults with displaced and undisplaced hip fractures
1 finding from 1 review
HRQoL: using EQ‐5D (range from 0 to 1; higher values indicate better quality of life · adults with displaced and undisplaced hip fractures
1 finding from 1 review
Patient satisfaction NRS from 0 to 10 or 4‐step Likert scale The higher the score, the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as moderately difficulta
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction NRS from 0 to 10 or 4‐step Likert scale The higher the score, the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as easya
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction NRS from 0 to 10 or 4‐step Likert scale The higher the score, the higher the level of satisfaction · adults undergoing peripheral venous cannulation classed as difficulta
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Resolution of symptoms · epidemic keratoconjunctivitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low